



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/630,397	07/29/2003	E. Premkumar Reddy	06056-0272RE1	8371
23973	7590	09/15/2005	EXAMINER	
DRINKER BIDDLE & REATH ATTN: INTELLECTUAL PROPERTY GROUP ONE LOGAN SQUARE 18TH AND CHERRY STREETS PHILADELPHIA, PA 19103-6996			POWERS, FIONA	
			ART UNIT	PAPER NUMBER
			1626	
DATE MAILED: 09/15/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/630,397	REDDY ET AL.
	Examiner Fiona T. Powers	Art Unit 1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 18 July 2005.
- 2a) This action is FINAL.                            2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-7 and 9-54 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) 1-7, 9-19, 24, 25, 27-33 and 48-54 is/are allowed.
- 6) Claim(s) 20-23 and 34-47 is/are rejected.
- 7) Claim(s) 26 is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

Art Unit: 1626

Receipt is acknowledged of the amendment filed July 18, 2005. The amendment is objected to as being in improper format. All amendments must be made under 37 C.F.R. 1.173 and must be relative to the original patent claims (not the last amendment). Strikethrough is also not permitted.

Claim 26 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

In claim 26, X is a radical of the formula II. However, in claim 24 on which it is dependent, X is only trihalomethyl.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 20 to 23 and 34 to 47 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating inflammation, does not reasonably provide enablement for treating cyclooxygenase-mediated disorder, inflammation-mediated disorder, neoplasia, angiogenesis-mediated disorder and neoplasia that expresses a

Art Unit: 1626

cyclooxygenase. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph are as follows:

1. the nature of the invention,
2. the state of the prior art,
3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of skill in the art.

See *In re Wands*, 8 USPQ2d 1400.

The nature of the invention is treating cyclooxygenase-mediated disorder, inflammation-mediated disorder, neoplasia, angiogenesis-mediated disorder and neoplasia that expresses a cyclooxygenase.

The state of the prior art is that the pharmacological art involves screening *in vitro* and *in vivo* to determine which compounds exhibit the desired pharmacological activities (i.e.

Art Unit: 1626

what compounds can treat which specific diseases and by what mechanism). There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 166 USPQ 18 indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute.

Applicants are claiming the treatment of cyclooxygenase-mediated disorder, inflammation-mediated disorder, neoplasia, angiogenesis-mediated disorder and neoplasia that expresses a cyclooxygenase. The state of the prior art is that cancer therapy remains highly unpredictable. The various types of cancers have different causative agents, involve different cellular mechanisms, and consequently, differ in treatment protocol. It is known that the challenge of cancer treatment has been to target specific therapies to pathogenetically distinct tumor types, that cancer classification has been based on primarily on morphological appearance of the tumor and that tumors with similar histopathological appearance can follow

Art Unit: 1626

significantly different clinical courses and show different responses to therapy (Golub et al. page 531). Furthermore, it is known that chemotherapy is most effective against tumors with rapidly dividing cells and that cells of solid tumors divide relatively slowly and chemotherapy is often less effective against them.

The only direction or guidance present in the instant specification is a cyclooxygenase enzyme assay and a soft agar assay to determine the percent inhibition of human colorectal carcinoma cells. There are no working examples present for the treatment of any cyclooxygenase-mediated disorder, neoplasia, neoplasia that expresses a cyclooxygenase, inflammation-mediated disorder, angiogenesis-mediated disorder.

The breadth of the claims is treating cyclooxygenase-mediated disorder, inflammation-mediated disorder, neoplasia, angiogenesis-mediated disorder and neoplasia that expresses a cyclooxygenase.

The quantity of experimentation needed is undue experimentation. One of skill in the art would need to determine what diseases would be benefited (treated) by inhibition of cyclooxygenase and would then have to determine which of the claimed compounds would provide treatment of which disease, if any.

Art Unit: 1626

The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by in vitro and in vivo screening to determine which compounds exhibit the desired pharmacological activity and which diseases would benefit from this activity.

Thus, the specification fails to provide sufficient support of the broad use of the compound of the instant claims for the treatment of any cyclooxygenase-mediated disorder, inflammation-mediated disorder, neoplasia, angiogenesis-mediated disorder and neoplasia that expresses a cyclooxygenase. As a result necessitating one of skill to perform an exhaustive search for which diseases can be treated by what compounds of the instant claims in order to practice the claimed invention.

Genetech Inc. v. Novo Nordisk A/S 42 USPQ2d 1001 states that "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

Therefore, in view of the Wands factors and In re Fisher discussed above, to practice the claimed invention herein, one

Art Unit: 1626

of skill in the art would have to engage in undue experimentation to test which diseases can be treated by the compound encompassed in the instant claims, with no assurance of success.

Applicant's arguments filed July 18, 2005 have been fully considered but they are not persuasive. Applicants cite various literature references to show that cyclooxygenase inhibitors, particularly COX-2 inhibitors are useful in treating tumors that express cyclooxygenase. However, none of the references shows that cyclooxygenase inhibitors that are similar in structure to the claimed compounds are useful to treat tumors. Furthermore, the references only show that specific cyclooxygenase inhibitors are useful to treat specific types of tumors such as pancreatic cancer. Applicants have amended claim 40 to recite that the treatment of neoplasia that expresses a cyclooxygenase. Neoplasias that express a cyclooxygenase vary widely and include cancers of the brain, bone, epithelial, adenocarcinoma, small bowel, stomach, esophagus, mouth, lip, pancreas, bladder, liver, colon, pancreas, ovary, cervix, lung, breast and skin etc. Applicants' specification only shows the percent inhibition of human colorectal carcinoma cells and thus cannot be used to support the treatment of all neoplasias that express cyclooxygenase.

Art Unit: 1626

Claims 1 to 7, 9 to 19, 24, 25, 27 to 33 and 48 to 54 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fiona T. Powers whose telephone number is 571-272-0702. The examiner can normally be reached on Monday - Friday 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*Fiona T. Powers*  
Fiona T. Powers  
Primary Examiner  
Art Unit 1626

Application/Control Number: 10/630,397  
Art Unit: 1626

Page 9

ftp  
September 7, 2005